- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00028613
Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
Phase I Safety Study Of 131I-Lym-1 For The Treatment Of Previously Treated Diffuse Large B-Cell Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances such as radioactive iodine to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibodies in treating patients who have large cell lymphoma that has been previously treated.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
- Determine the maximum tolerated dose of iodine I 131 monoclonal antibody Lym-1 in patients with previously treated diffuse large cell lymphoma.
- Determine the safety of this drug in these patients.
- Determine the response of patients to this drug.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive unlabeled monoclonal antibody Lym-1 IV over 40 minutes followed 15-30 minutes later by iodine I 131 monoclonal antibody Lym-1 IV over 2 minutes.
Cohorts of 3-6 patients receive escalating doses of iodine I 131 monoclonal antibody Lym-1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed weekly for 8 weeks and then every 3 months for 1 year.
PROJECTED ACCRUAL: A total of 8-36 patients will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106-5065
- Ireland Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria
- Histologic diagnosis of B-cell diffuse large cell lymphoma (REAL classification system) confirmed by an independent central pathology reviewer.
- The tumor's B-cell phenotype will be confirmed by positive L-26 (CD20).
- Previous treatment with 2 common combination chemotherapy regimens. Patients previously treated with unlabeled monoclonal antibody therapy are eligible.
- Men or women at least 18 years of age.
- Karnofsky Performance Score (KPS) estimated to be > 60 at the time of the scheduled therapeutic dose of 131I-Lym-1.
- Life expectancy estimated to be at least 3 months from the time of the therapeutic dose of 131I Lym-1.
- Measurable disease demonstrable by physical examination or computerized tomography (CT).
- CT scan evidence of at least one indicator lesion with at least one diameter that measures > 2 cm. (The CT scan should be done within 2 weeks of the imaging study.)
Exclusion Criteria
- Inability or unwillingness to comply with the following:
- Bone marrow biopsy
- Return for follow-up visits
- Remaining motionless for extended periods of time for imaging procedures
- Serial blood/urine sampling (for dosimetry patients only)
- Pregnancy (Women of childbearing potential must be practicing an effective method of contraception.)
- Presence of a second malignancy except for basal cell skin carcinoma or carcinoma in-situ of the cervix
- Presence of active lymphomatous meningitis or other CNS involvement with lymphoma.
- HIV positive patients.
- Prior total body irradiation, or a course of prior radiation > 3,000 cGy delivered to > 20% of the central marrow or the lumbar vertebrae within 6 months of screening.
- Serum creatinine or total bilirubin > 2 x the upper limit of normal.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase > 3 x the upper limit of normal.
- Significant marrow lymphoma (defined as lymphoma cells constituting greater than 20% of the hematopoietic marrow elements from an iliac crest biopsy). A prior bone marrow biopsy is acceptable if it meets the following criteria:
- If there is prior bone marrow involvement, the biopsy must be performed within 45 days of screening.
- If there is no prior bone marrow involvement, the biopsy must be performed within 90 days of screening
- WBC count < 3,500/mm3, granulocyte count < 1,500/mm3, or platelet count < 125,000/mm3.
- Positive human anti-mouse antibodies (HAMA) serum values, defined as > 74 ng/mL at screening.
- Patients who have not recovered from toxicities of most recent anti-lymphoma therapy.
- Treatment with:
- Colony stimulating factor G-CSF or GM-CSF within 120 hours of screening laboratory assessment.
- Erythropoietin (EPO) within a month of screening laboratory assessment
- Whole blood or platelet transfusion within 120 hours of screening laboratory assessment
- History or electrocardiographic (ECG) evidence of Q-wave myocardial infarction within 6 months of screening or congestive heart failure (CHF; NYHA Stage III or IV).
- Known hypersensitivity to iodine or iodine-containing organic substances.
- Patients who require therapy with anticoagulants or antiplatelet drugs which cannot be discontinued during the study.
- Patients who are known to have antiplatelet antibodies.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Omer N. Koc, MD, Case Comprehensive Cancer Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- BRLX1400
- CWRU-BRLX-1400
- BRLX-303680
- CWRU-090036
- NCI-G01-2038
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op iodine I 131 monoclonal antibody Lym-1
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Actief, niet wervendRecidiverend schildkliercarcinoom | Slecht gedifferentieerd schildkliercarcinoom | Stadium IV Schildklier Folliculair Carcinoom AJCC v7 | Stadium IV Schildklier Papillair Carcinoom AJCC v7 | Stadium IVA Folliculair carcinoom van de schildklier AJCC v7 | Stadium IVA Schildklier Papillair Carcinoom... en andere voorwaardenVerenigde Staten
-
Peregrine PharmaceuticalsVoltooidRecidiverend multiform glioblastoomVerenigde Staten
-
Hospital for Special Surgery, New YorkVoltooidAnalyse van het bloedvolumeVerenigde Staten
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)VoltooidExtranodale marginale zone B-cellymfoom van slijmvliesgeassocieerd lymfoïde weefsel | Nodale marginale zone B-cellymfoom | Recidiverend volwassen Burkitt-lymfoom | Recidiverend diffuus grootcellig lymfoom bij volwassenen | Recidiverend diffuus gemengd cellymfoom bij volwassenen | Recidiverend... en andere voorwaardenVerenigde Staten
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)VoltooidHersenen en tumoren van het centrale zenuwstelselVerenigde Staten
-
Peregrine PharmaceuticalsVoltooidHersenen en tumoren van het centrale zenuwstelselVerenigde Staten
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)BeëindigdAcute myeloïde leukemie als gevolg van eerder myelodysplastisch syndroom | Chronische myelomonocytische leukemie | Eerder behandeld myelodysplastisch syndroom | Volwassen acute myeloïde leukemie in remissie | Volwassen acute lymfoblastische leukemie in remissie | Refractaire bloedarmoede met... en andere voorwaardenVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKlineVoltooid
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendNeuroblastoom | GanglioneuroblastoomVerenigde Staten, Canada, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendGelokaliseerd resectabel neuroblastoom | Gelokaliseerd inoperabel neuroblastoom | Regionaal neuroblastoom | Stadium 4S neuroblastoom | Ganglioneuroblastoom | Stadium 4 neuroblastoomVerenigde Staten